Related Experiment Video
Updated: May 1, 2026
A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
New therapeutics for osteoporosis
1University of Melbourne, Department of Medicine, St. Vincent's Institute of Medical Research, 9 Princes Street, Fitzroy 3065, Victoria, Australia.
Abstract:
Two new approaches for the treatment of osteoporosis are summarized, each having arisen out of important new discoveries in bone biology. Odanacatib (ODN) inhibits the enzyme, cathepsin K, that is essential for the resorbing activity of osteoclasts. It is effective in preventing ovariectomy-induced bone loss in preclinical studies, and a phase II clinical study has shown inhibition of resorption sustained over five years. Outcome of a phase III study is awaited. The finding from mouse and human genetics that Wnt signaling is a powerful inducer of bone formation led to developments aimed at enhancing this pathway. Of the several approaches towards this, the most advanced is with a neutralizing antibody against sclerostin, the osteocyte-derived inhibitor of Wnt signaling. Preclinical studies show a powerful bone anabolic effect, and a clinical phase II study shows dose-dependent increases in bone formation and decreases in bone resorption markers.
Insights
Two novel osteoporosis treatments target osteoclast activity and Wnt signaling pathways. Odanacatib inhibits bone resorption, while sclerostin antibodies promote bone formation, showing promise in clinical trials.
Area of Science:
- Bone Biology
- Pharmacology
- Genetics
Background:
- Osteoporosis treatment is evolving with new discoveries in bone biology.
- Osteoclast activity and Wnt signaling pathways are key targets for therapeutic intervention.
Purpose of the Study:
- To summarize two novel therapeutic approaches for osteoporosis.
- To highlight advancements in targeting bone resorption and formation.
Main Methods:
- Odanacatib (ODN) development targeting cathepsin K, an enzyme crucial for osteoclast function.
- Development of a neutralizing antibody against sclerostin to enhance Wnt signaling for bone formation.
Main Results:
- Odanacatib demonstrated efficacy in preventing bone loss and sustained inhibition of resorption over five years in preclinical and Phase II studies.
- Sclerostin antibody showed potent bone anabolic effects in preclinical studies and dose-dependent increases in bone formation markers in Phase II trials.
Conclusions:
- New therapeutic strategies targeting cathepsin K and Wnt signaling show significant promise for osteoporosis treatment.
- Further clinical evaluation, including Phase III studies for Odanacatib, is anticipated to confirm efficacy and safety.
Related Concept Videos
01:31Osteoclasts in Bone Remodeling
01:40Bone Remodeling
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:25Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
01:31Bone Remodeling and Repair